[en] Acquisition of invasive/metastatic potential through protease expression is an essential event in tumor progression. High levels of components of the plasminogen activation system, including urokinase, but paradoxically also its inhibitor, plasminogen activator inhibitor 1 (PAI1), have been correlated with a poor prognosis for some cancers. We report here that deficient PAI1 expression in host mice prevented local invasion and tumor vascularization of transplanted malignant keratinocytes. When this PAI1 deficiency was circumvented by intravenous injection of a replication-defective adenoviral vector expressing human PAI1, invasion and associated angiogenesis were restored. This experimental evidence demonstrates that host-produced PAI is essential for cancer cell invasion and angiogenesis.
Disciplines :
Biochemistry, biophysics & molecular biology
Author, co-author :
Bajou, Khalid ; Université de Liège - ULiège > Département des sciences de la vie > Biologie et génétique moléculaire
Noël, Agnès ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire appliquée à l'homme
Gerard, R. D.
Masson, Véronique ; Centre Hospitalier Universitaire de Liège - CHU > Gynécologie-Obstétrique CHR
Brunner, N.
Holst-Hansen, C.
Skobe, M.
Fusenig, N. E.
Carmeliet, P.
Collen, D.
Foidart, Jean-Michel ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie - Obstétrique
Language :
English
Title :
Absence of Host Plasminogen Activator Inhibitor 1 Prevents Cancer Invasion and Vascularization
Publication date :
August 1998
Journal title :
Nature Medicine
ISSN :
1078-8956
eISSN :
1546-170X
Publisher :
Nature Publishing Group, New York, United States - New York
Blasi, F. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 15, 105-111 (1993).
Mignatti, P. & Rifkin, D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73, 161-195 (1993).
Murphy, G., Atkinson, S., Ward, R., Gavrilovic, J. & Reynolds, J.J. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann. NY Acad. Sci. 667, 1-12 (1992).
Andreasen, P.A., Kjoller, L., Christensen, L. & Duffy, M.J. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer 72, 1-22 (1997).
Ossowski, L., Russo-Payne, H. & Wilson E.L. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res. 51, 274-281 (1991).
Yu, H.R. & Schultz R.M. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res. 50, 7623-7633 (1990).
Heiss, M.M. et al. Tumor associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J. Clin. Oncol. 13, 2084-2093 (1995).
Pyke, C., Kristensen, P., Ralfkiaer, E., Eriksen, J. & Dano, K. The plasminogen activation system in human colon cancer: messenger RNA for the inhibitor PAI-1 is located in endothelial cells in the tumor stroma. Cancer Res. 51, 4067-4071 (1991).
Sier, C.F.M. et al. Inactive urokinase and increased levels of its inhibitor type I in colorectal cancer liver metastasis. Gastroenterology 107, 1449-1456 (1994).
Liu, G., Shuman M.A. & Cohen R.L. Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. Int. J. Cancer 60, 501-506 (1995).
Grondhal-Hansen, J. et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53, 2513-2521 (1993).
Pedersen, H. et al. Prognostic impact of urokinase, urokinase receptor, and type I plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res. 54, 4671-4675 (1994).
Kuhn, W. et al. Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol. Oncol. 55, 401-409 (1994).
Kruithof, E.K., Gudinchet, A., & Bachmann, F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb. Haemost. 59, 7-12 (1988).
Deng, G., Curriden, S.A., Wang, S., Rosenberg, S. & Loskutoff, D.J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol. 134, 1-9 (1996).
Chapman, H.A. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell. Biol. 9, 714-724(1997).
Fusenig, N.E., Amer, S.M., Boukamp, P. & Worst, K.M. Characteristics of chemically transformed mouse epidermal cells in vitro and in vivo. Bull. Cancer 65, 271-280 (1978).
Carmeliet, P. et al. Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. J. Clin. Invest. 92, 2746-2755 (1993).
Carmeliet, P. et al. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J. Clin. Invest. 92, 2756-2760 (1993).
DeClerck, P.J., Verstreken, M. & Coolen, D. Immunoassay of murine t-PA, uPA and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thomb Haemost. 74, 1 305-1 309 (1995).
Lijnen, R.H., Moons, L., Beelen, V., Carmeliet, P. & Collen, D. Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice. Thromb. Haemost. 74, 1126-1131(1995).
Nakamura, M. et al. Possible rote of plasminogen activator inhibitor 2 in the prevention of the metastasis of gastric cancer tissue. Thromb. Res. 65, 709-719 (1992).
Nakarda, H. et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res. 54, 2900-2907 (1994).
Foekens, J.A. et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J. Clin. Oncol. 12, 1648-1658 (1994).
Bacharach, E., Itin, A., & Keshet, E. In vivo patterns of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. Proc. Natl. Acad. Sci. USA 89, 1 0686-1 0690 (1992).
Bianchi, E. et al. Immunohistochemical localization of plasminogen activator inhibitor-1 in breast cancer. Int. J. Cancer 60, 597-603 (1995).
Schnaper, H.W. et al. Plasminogen activators augment endothelial organization in vitro by two distinct pathways. J. Cell. Physiol. 165, 107-118 (1995).
Montesano, R. et al. Increased proteolytic activity is responsible for the aberrant morphogenetic behavior of endothelial cells expressing the middle T oncogene. Cell 62, 435-445 (1990).
Pepper, M.S., Sappino, A.P., Montesano, R., Orci, L. & Vassalli, J.-D. Plasminogen activator inhibitor-1 is induced in migrating endothelial cells. J. Cell. Physiol. 153, 129-139 (1992).
Kanse, S.M., Kost, C., Wilhelm, O.G., Andreasen, P.A. & Preissner, K.T. The urokinase receptor is a major vitronectin-binding protein on endothelial cells. Exp. Cell Res. 224, 344-353 (1996).
Stefansson, S. & Lawrence, D.A. The serpin PAI-1 inhibits cell migration by blocking integrin αvβ3 binding to vitronectin. Nature 383, 441-443 (1996).
Waltz, D.A., Natkin, L.R., Fujita, R.M., Wei, Y. & Chapman H. A. Plasmin and plasminogen activator type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. 100, 58-67 (1997).
Boukamp, P., Stanbridge, E.J., Foo, D.Y., Cerutti, P.A. & Fusenig, N.E. c-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy. Cancer Res. 50, 2840-2847 (1990).
Fusenig, N.E. in The Keratinocyte Handbook. (eds. Leigh, I., Lane, B., Watt, F.) 71-49 (Cambridge Univ. Press, Cambridge, 1994).
Carmeliet, P., Moons, L., Ploplis, V., Plow, E. & Collen, D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J. Clin. Invest. 99, 200-208 (1997).
Kristensen, P., Pyke, C., Lund, L.R., Andreasen, P.A. & Dano, K. Plasminogen activator inhibitor-type 1 in Lewis lung carcinoma. Histochemistry 93, 559-566 (1990).
Kristensen, P., Eriksen, J., Blasi, F. & Dano, K. Two alternatively spliced mouse urokinase receptor mRNAs with different histological localisation in the gastrointestinal tract. J. Cell Biol. 115, 1763-1771 (1991).
de Vries, T.J., Kitson, J.L., Silvers, W.K. & Mintz, B. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice. Cancer Res. 55, 4681-4687 (1995).
Sappino, A.P. et al. Differential protease expression by cutaneous squamous and basal cell carcinomas. J. Clin. Invest. 88, 1073-1079 (1991).
Carmeliet, P. et al. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 96, 3180-3191 (1997).